Fundraising Fox
EBR Systems
OTC: EBRCZSilicon Valley, AU · Founded 2003 · Delaware corporation · 157 employees on LinkedIn · 5 known investors
Find your way into EBR Systems
Sign up to see every warm intro you have to EBR Systems
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EBR Systems team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EBR Systems develops the WiSE cardiac pacing system, a leadless and physiologic medical device for treating heart failure patients. The company serves physicians and hospitals providing cardiac rhythm management and conduction system pacing solutions.
Founders & leadership
EBR Systems was founded in 2003 by Parker Willis.
AW
Allan WillExecutive ChairAllan Will is Executive Chair of EBR Systems and Chair of Setpoint Medical. He has founded or led multiple medical device companies including Ardian (sold to Medtronic), AneuRx (acquired by Medtronic), and Devices for Vascular Intervention (acquired by Eli Lilly), and was founding Managing Director of Split Rock Partners and founding Chair & CEO of The Foundry medical device incubator.
JM
John McCutcheonPresident, Chief Executive OfficerJohn McCutcheon is President and CEO of EBR Systems, which develops the WiSE cardiac pacing system for heart failure patients. He has experience in medical device development, clinical trial design and management, venture and public capital raising, and board management.
MC
Mark CowanVP, Engineering2003–2017Mark Cowan is Executive Officer at EBR Systems, which develops the WiSE cardiac pacing system for heart failure treatment. He brings expertise in implantable and invasive medical devices, ultrasound-based systems, and medical device regulatory and safety practices.
SO
Stephen O'ConnerExecutive
RR
Richard RileyNamed on SEC filing
LR
Leighton ReadNamed on SEC filing
Board
DS
CN
Chris NaveBoard director
TM
Trevor MoodyBoard director
JJ
Joshua J. BaltzellBoard director
WS
William StarlingBoard director
Investors · 5
Emergent Medical Partners, LLPlisted by Emergent Medical Partners, LLPSan Jose
How we know: Emergent Medical Partners, LLP's portfolio page · Not right? Tell us
Runway Growth Capitallisted by Runway Growth CapitalMenlo Park
How we know: Runway Growth Capital's portfolio page · Not right? Tell us
MorgenthalerreportedPortola Valley
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$84.6M disclosed across 4 rounds · 2014–2021
▶$8.7MraisedJul 2021 · 36 investors · Other Health CareRule 506(c)
▶$8.7MraisedJul 2021 · 36 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- ALLAN WILLExecutive Officer, Director
- JOHN MCCUTCHEONExecutive Officer, Director
- DAVID STASSENDirector
- LEIGHTON READDirector
- TREVOR MOODYDirector
- CHRIS NAVEDirector
- Offering amount
- $25M
- Amount sold
- $8.7M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$16.2MraisedOct 2019 · 35 investors · Other Health CareRule 506(c)
▶$16.2MraisedOct 2019 · 35 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- ALLAN WILLExecutive Officer, Director
- JOHN MCCUTCHEONExecutive Officer, Director
- SUZANNE PILKINGTONExecutive Officer
- LEIGHTON READDirector
- TREVOR MOODYDirector
- CHRIS NAVEDirector
- DAVID STASSENDirector
- Offering amount
- $38.7M
- Amount sold
- $16.2M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$41MraisedNov 2017 · 29 investors · Other Health CareRule 506(b)
▶$41MraisedNov 2017 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Dave StassenDirector
- Chris NaveDirector
- Richard RileyExecutive Officer
- Allan R. WillExecutive Officer, Director
- Trevor MoodyDirector
- Leighton ReadDirector
- Offering amount
- $56M
- Amount sold
- $41M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.7MraisedJul 2014 · 18 investors · Other Health CareRule 506(b)
▶$18.7MraisedJul 2014 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Allan R. WillExecutive Officer, Director
- Parker WillisExecutive Officer
- Mark CowanExecutive Officer
- Joshua J. BaltzellDirector
- Stephen O'ConnerExecutive Officer
- Stephen H. MahleDirector
- William StarlingDirector
- David MilneDirector
- Thomas FogartyDirector
- John MaroneyDirector
- Richard E. RileyExecutive Officer, Director
- Offering amount
- $35.6M
- Amount sold
- $18.7M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
PerxBrandon Capital is a venture capital firm that transforms medical research breakthroughs into therapeutic products, supporting life science companies from early-stage through commercialization. The firm operates across Australia, New Zealand, and globally, with a focus on building a sustainable biotech industry.
Companies working in the same space as EBR Systems.
Frequently asked questions
- What does EBR Systems do?
- EBR Systems develops the WiSE cardiac pacing system, a leadless and physiologic medical device for treating heart failure patients. The company serves physicians and hospitals providing cardiac rhythm management and conduction system pacing solutions.
- Who founded EBR Systems?
- EBR Systems was founded by Parker Willis in 2003.
- Who are EBR Systems's investors?
- EBR Systems's investors include Ascension Ventures, Emergent Medical Partners, LLP, Runway Growth Capital, Morgenthaler, Split Rock Partners.
- How much funding has EBR Systems raised?
- EBR Systems has disclosed $84.6M raised across 4 rounds.
- Where is EBR Systems headquartered?
- EBR Systems is headquartered in Silicon Valley, AU.